- Home
- ESGR vs NUVL Comparison
ESGR vs NUVL Comparison
Compare ESGR & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGR
- NUVL
- Stock Information
- Founded
- ESGR 2001
- NUVL 2017
- Country
- ESGR Bermuda
- NUVL United States
- Employees
- ESGR N/A
- NUVL N/A
- Industry
- ESGR Property-Casualty Insurers
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- ESGR Finance
- NUVL Health Care
- Exchange
- ESGR Nasdaq
- NUVL Nasdaq
- Market Cap
- ESGR 4.7B
- NUVL 5.5B
- IPO Year
- ESGR N/A
- NUVL 2021
- Fundamental
- Price
- ESGR $332.00
- NUVL $79.49
- Analyst Decision
- ESGR
- NUVL Strong Buy
- Analyst Count
- ESGR 0
- NUVL 11
- Target Price
- ESGR N/A
- NUVL $112.36
- AVG Volume (30 Days)
- ESGR 93.0K
- NUVL 420.4K
- Earning Date
- ESGR 03-04-2025
- NUVL 03-04-2025
- Dividend Yield
- ESGR N/A
- NUVL N/A
- EPS Growth
- ESGR 51.73
- NUVL N/A
- EPS
- ESGR 66.06
- NUVL N/A
- Revenue
- ESGR $1,067,000,000.00
- NUVL N/A
- Revenue This Year
- ESGR N/A
- NUVL N/A
- Revenue Next Year
- ESGR N/A
- NUVL N/A
- P/E Ratio
- ESGR $5.03
- NUVL N/A
- Revenue Growth
- ESGR 17.90
- NUVL N/A
- 52 Week Low
- ESGR $275.02
- NUVL $61.80
- 52 Week High
- ESGR $348.48
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- ESGR 74.06
- NUVL 43.83
- Support Level
- ESGR $331.22
- NUVL $77.84
- Resistance Level
- ESGR $333.36
- NUVL $85.21
- Average True Range (ATR)
- ESGR 1.29
- NUVL 3.78
- MACD
- ESGR 0.37
- NUVL -0.46
- Stochastic Oscillator
- ESGR 80.03
- NUVL 12.08
About ESGR Enstar Group Limited
Enstar Group Ltd is a (re)insurance group that offers capital release solutions through its network of group companies. It seeks to create value by managing (re)insurance companies and portfolios of (re)insurance and other liability businesses in run-off and striving to generate an attractive risk-adjusted return from its investment portfolio. Its operations are through four reportable segments: Run-off, Assumed Life, Investments, and Legacy Underwriting.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.